Deferasirox - DisperSol Technologies

Drug Profile

Deferasirox - DisperSol Technologies

Alternative Names: K-DFX

Latest Information Update: 22 Feb 2017

Price : $50

At a glance

  • Originator DisperSol Technologies
  • Class Benzoic acids; Small molecules; Triazoles
  • Mechanism of Action Chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Iron overload

Most Recent Events

  • 22 Feb 2017 Chemical structure information added
  • 24 Nov 2016 K DFX is available for licensing as of 24 Nov 2016. http://www.dispersoltech.com/pipeline/
  • 23 Nov 2016 Phase-I clinical trials in Iron overload in USA (PO) (Dispersol Technologies website, November 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top